Amgen Delays Phase III Trials Of AMG-706 Due To Cholecystitis Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim data from Phase II gastrointestinal stromal cancer trials showed 2%-3% of patients developed cholecystitis.